Migraine drug rimegepant under Real-World review in greater bay area
NCT ID NCT06221267
First seen May 22, 2026 · Last updated Jun 19, 2026 · Updated 4 times
Summary
This completed registry study followed 120 migraine patients in the Guangdong-Hong Kong-Macao Greater Bay Area who were prescribed rimegepant by their doctors. The goal was to see how the drug affects their quality of life, daily functioning, work productivity, and overall satisfaction in a real-world setting. Researchers collected data using standard questionnaires but did not give any treatment or change how patients used the medication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
Guangzhou, Guangdong, 510120, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
rimegepant
What this could lead to
If successful, this study could provide real-world evidence on how rimegepant improves quality of life and daily functioning for migraine patients.
What could go wrong
This is an observational registry study, not a controlled trial, so results may be influenced by patient selection or other factors. It does not test new effectiveness or safety beyond what is already known.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.